BMS is lead player in patent-approval race

Which biopharma company was granted the most pharma patents last year? Pharmalot asked IFI Patent Intelligence the question and came up with Bristol-Myers Squibb, with 82. Wyeth, Pfizer, Hoffman LaRoche, Merck, AstraZeneca and Eli Lilly followed in due order of innovation. These are all class 514 patents approvals, as distinct from filings. As Pharmalot points out, there is always a hefty backlog of patent filings. Interestingly, Sanofi-Aventis, which has been hammered by the analysts for its thin pipeline, came out near the bottom of the list, behind the University of California. Tech companies put the biopharma industry to shame though. IBM alone filed 3,148 patents last year.

- read the report from Pharmalot

Suggested Articles

The oral direct-acting antiviral is set to enter a phase 3 trial in non-hospitalized patients early next year.

RA Capital 's 15-month old inaugural venture fund that has already seen 25% of its portfolio companies IPO or be acquired. 

Dania Rabah, Ph.D., has become the new chief scientific officer at startup Rheos Medicines, coming off a stint at Biogen.